Want to see SYK full AI Analyst Report?
SYK Stock Chart & Stats
$329.67
$11.28(3.54%)
At close: 4:00 PM EDT
$329.67
$11.28(3.54%)
Day’s Range― - ―
52-Week Range$267.00 - $392.55
Previous CloseN/A
Volume2.37M
Average Volume (3M)2.87M
Market Cap
$116.76B
Enterprise Value$133.50B
Total Cash (Recent Filing)$3.48B
Total Debt (Recent Filing)$14.94B
Price to Earnings (P/E)30.6
Beta0.55
Next Earnings
Oct 29, 2026EPS Estimate
3.55Next Dividend Ex-DateN/A
Dividend Yield1.18%
Share Statistics
EPS (TTM)9.73
Shares Outstanding383,573,060
10 Day Avg. Volume2,522,532
30 Day Avg. Volume2,874,232
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue5.17
Enterprise Value/Gross Profit7.93
Enterprise Value/Ebitda19.95
Forecast
1Y Price Target
$364.72Price Target Upside10.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)14.96
Revenue Forecast (FY)$27.19B
Bulls Say, Bears Say
Bulls Say
Organic Growth And Margin ExpansionStrong organic growth combined with expanding gross and operating margins indicates broad commercial momentum and operating leverage. If sustained, this performance can support reinvestment in product development, strengthen market share, and provide a durable foundation for earnings growth.
Strong Cash Generation And DeleveragingRobust free cash flow gives Stryker capacity to fund innovation, acquisitions, debt reduction, and shareholder returns without relying exclusively on external financing. The concurrent decline in leverage improves financial flexibility and supports resilience through changing operating or funding conditions.
Product Innovation PipelineRegulatory clearance for Sonopet 3 adds another commercial product to Stryker’s surgical technology portfolio and demonstrates continued innovation. New platforms can deepen customer relationships, expand procedure coverage, and create recurring utilization-linked revenue after launch.
Bears Say
Sizable Absolute DebtAlthough leverage has improved, the remaining debt balance is substantial and creates an ongoing obligation for interest, repayment, and refinancing management. Higher financing needs from acquisitions or rising rates could reduce capital-allocation flexibility and weigh on resilience.
Cash Conversion VariabilityOperating cash flow below EBITDA means reported operating performance does not always translate fully into cash during the period. Recurring working-capital or cash-cost timing effects could constrain funds available for acquisitions, debt reduction, and other strategic investments.
Residual Cybersecurity CostsOngoing remediation and elevated technology-related spending can keep costs above normal levels beyond the initial disruption. This may restrain near-term margin and earnings progression while management completes recovery work and restores more efficient operations.
SYK FAQ
What was Stryker Corporation’s price range in the past 12 months?
Stryker Corporation lowest stock price was $267.00 and its highest was $392.55 in the past 12 months.
What is Stryker Corporation’s market cap?
Stryker Corporation’s market cap is $116.76B.
When is Stryker Corporation’s upcoming earnings report date?
Stryker Corporation’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.
How were Stryker Corporation’s earnings last quarter?
Stryker Corporation released its earnings results on Jul 30, 2026. The company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.488 by $0.202.
Is Stryker Corporation overvalued?
According to Wall Street analysts Stryker Corporation’s price is currently Undervalued.
Does Stryker Corporation pay dividends?
Stryker Corporation pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 1.18%. See more information on Stryker Corporation dividends here
What is Stryker Corporation’s EPS estimate?
Stryker Corporation’s EPS estimate is 3.55.
How many shares outstanding does Stryker Corporation have?
Stryker Corporation has 383,573,060 shares outstanding.
What happened to Stryker Corporation’s price movement after its last earnings report?
Stryker Corporation reported an EPS of $3.69 in its last earnings report, beating expectations of $3.488. Following the earnings report the stock price went down -6.419%.
Which hedge fund is a major shareholder of Stryker Corporation?
Currently, no hedge funds are holding shares in SYK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stryker Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$364.72 (10.63% Upside)
$364.72 (10.63% Upside)
Blogger Sentiment
Bullish
SYK Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 558.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $118.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.76%
12-Months-Change
Fundamentals
Return on Equity
16.36%
Trailing 12-Months
Asset Growth
3.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
SYK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad recovery and operational momentum: solid organic growth (9%), a strong adjusted EPS beat (+17.9%), expanding margins, record Mako performance, multiple product launches and healthy cash generation/backlog. Key negatives were an acute supply disruption in peripheral vascular (Inari) that drove a U.S. vascular decline (‑6.7%), lingering costs and absorption effects from the prior cybersecurity incident, and some launch timing variability. Management expects backorders to be manageable by end of Q3 and reiterated confidence in the full‑year outlook and capital demand, so positives materially outweigh manageable near‑term headwinds.View all SYK earnings summariesSYK Net sales Breakdown
62.30% MedSurg and Neurotechnology
37.70% Orthopaedics and Spine

SYK Stock 12 Month Forecast
Average Price Target
$364.72
▲(10.63% Upside)
Technical Analysis
Integra Lifesciences
―
Medtronic
―
Smith & Nephew Snats
―
Zimmer Biomet Holdings
―
Globus Medical
―
Ownership Overview
3.90% Insiders
19.33% Mutual Funds
2.22% Other Institutional Investors
53.81% Public Companies and Individual Investors











